With ATP sites on Kir6.2 that inhibit activity and ADP sites on SUR1 that antagonize the inhibition, ATP-sensitive potassium channels (KATP channels) are designed as exquisite sensors of adenine nucleotide levels that signal changes in glucose metabolism. If pancreatic KATP channels localize to the insulin secretory granule, they would be well positioned to transduce changes in glucose metabolism into changes in granule transport and exocytosis. Tests for pancreatic KATP channels localized to insulin secretory granules led to the following observations: fluorescent sulfonylureas that bind the pancreatic KATP channel specifically label intracellular punctate structures in cells of the endocrine pancreas. The fluorescent glibenclamides colocalize with Ins-C-GFP, a live-cell fluorescent reporter of insulin granules. Expression of either SUR1-GFP or Kir6.2-GFP fusion proteins, but not expression of GFP alone, directs GFP fluorescence to insulin secretory granules. An SUR1 antibody specifically labels insulin granules identified by anti-insulin. Two different Kir6.2 antibodies specifically label insulin secretory granules identified by anti-insulin. Immunoelectron microscopy showed Kir6.2 antibodies specifically label perimeter membrane regions of the secretory granule. Relatively little or no labeling of other structures, including the plasma membrane, was found. Our results demonstrate that the insulin secretory granule is the major site of KATP channels of the endocrine pancreas.

A major question in insulin secretion is the cellular site of action of sulfonylureas, which are taken daily by millions of diabetic subjects to correct hyperglycemia. One site of sulfonylurea action is at the cytoplasmic face of the plasma membrane sulfonylurea receptor (15) of the ATP-sensitive potassium channel (KATP channel) (6). Hundreds of KATP channels are localized to the plasma membrane of insulin-secreting β-cells (7). The pancreatic KATP channel comprises four regulatory sulfonylurea receptor (SUR1) subunits and four potassium pore-forming (Kir6.2) subunits (810). The plasma membrane KATP channel acts like an on/off switch. When on, potassium ions flow out through the channel electrically hyperpolarizing the β-cell, putting a brake on the signal flow controlling insulin secretion (11). When off, the KATP channel, which is inhibited by sulfonylureas or by the increased ATP/ADP ratio from glucose metabolism (12,13), removes this brake, allowing initiation of insulin release by elevating intracellular calcium (1417), which triggers the exocytotic fusion of insulin granule and β-cell membrane.

The calcium signal, however, is insufficient for regulating insulin release in response to glucose under typical conditions (11,18). While pharmacologically either opening or inhibiting the plasma membrane KATP channel, maneuvers that elevate not only intracellular calcium but also glucose metabolism are necessary to confer glucose dose dependency to stimulated insulin release. By an unknown mechanism, glucose metabolism provides a second controlling parameter that, more distal in the pathway, enhances the response of the insulin secretory granule to the calcium signal, allowing amplification of insulin release by elevated glucose metabolism. Study of the amplification pathway has implicated adenine nucleotides as one of the factors coupling glucose metabolic and insulin exocytotic rates (16,18,19). Designed for ATP and ADP sensing, KATP channels could confer graded glucose dose dependency in the amplification pathway in addition to their role as on/off switch at the plasma membrane, elevating intracellular calcium. Because the response of the insulin secretory granule is involved, the distal cellular site for the KATP channels might be the secretory granule. In this study, we used novel live cell confocal imaging, as well as classical immunohistochemical techniques, to test for pancreatic KATP channels localized to insulin secretory granules. We report on numerous lines of evidence indicating not only that pancreatic KATP channels localize to the secretory granule membrane but that it is their major site in the β-cell of the endocrine pancreas.

Islet isolation, infection, and culture.

Murine islets were isolated from BALB/c or C57BL/6 mice pancreata by collagenase digestion followed by separation on a Ficoll gradient and purified by hand under a stereo microscope (20). Recombinant Ad.Ins-C-GFP virus was used as described for islet infection (21). Islets were washed using serum-free culture medium and then the medium was nearly completely removed by pipeting, leaving ∼50 μl. The expression levels shown were typical after 1–3 days of infection. Native and infected islets were cultured in RPMI-1640 media containing 7.5 mmol/l glucose and 10% FCS and incubated at 37°C in 5% CO2. Live cells were used for the experiments reported here, as determined by the LIVE/DEAD Viability/Cytotoxicity Kit (Molecular Probes, Eugene, OR), granule exocytotic capacity, or both.

Fluorescent sulfonylurea labeling.

Green glibenclamide BODIPY FL and red glibenclamide BODIPY TR (Molecular Probes) were each used to achieve a final concentration of 40 nmol/l (22). Islets were washed using Krebs-Ringer buffer (in 7.5 mmol/l glucose) and then labeled by superfusion with the fluorescent glibenclamide within 60 min at 4°C until cellular fluorescence was readily detectable. The islets were then washed twice with Krebs-Ringer buffer and imaged.

Confocal fluorescence microscopy.

Islets were placed into an optical recording chamber (Harvard Apparatus, Holliston, MA) at 37°C. Single-photon confocal microscopy was performed using an Olympus Fluoview 300 Confocal Laser Scanning head with an Olympus IX70 inverted microscope (Olympus, Melville, NY). Excitation of GFP, green glibenclamide BODIPY FL, or green AlexaFluor 488 conjugated to secondary antibody was by the 488 nm Argon laser line and emission detected using sharp cutoff 510IF long-pass and BA530RIF short-pass filters for PMT 1. Excitation of red glibenclamide BODIPY TR or red AlexaFluor 594 conjugated to secondary antibody was by the 543-nm green HeNe laser line and emission detected using a sharp cutoff BA610IF long-pass filter for PMT 2. Coimaging was done by sequential excitation, and simultaneous detection of emission which showed no cross-talk was detectable under these excitation-detection conditions.

DNA constructs and expression

Green fluorescent protein within C-peptide of mouse insulin.

Live cell insulin granule fluorescent labeling with the Adlox recombinant, designated simply “Adlox.Ins-C-GFP,” was used as described (21).

Emerald GFP fused separately to COOH-termini of Mouse SUR1 and Kir6.2.

Overlap PCR was used to insert in-frame immediately after the coding sequence of mouse SUR1 or mouse Kir6.2 in pCS2 (23), with an eight-glycine codon linker between coding segments. The simian CMV promoter of pCS2 was used to express SUR1-GFP or Kir6.2-GFP fusions by incubating 4 μg DNA in 200 μl OptiMem media (Gibco/BRL, Gaithersburg, MD) in one tube and 8 μl Lipofectamine 2000 (Invitrogen, Carlsbad, CA) in 200 μl OptiMem media in a separate tube for 5 min at room temperature. The tubes were then combined, incubated for 20 min at room temperature, and added to islets.

KATP channel antibodies and confocal immunofluorescence microscopy.

We raised rabbit anti-mouse SUR1 antibodies against the 21 COOH-terminal amino acid residues of mouse SUR1 (KPEKLLSQKDSVFASFVRADK [24]), and they were affinity purified with the peptide. We raised rabbit anti-mouse Kir6.2 antibodies against either mouse Kir6.2 residues 377–390 (14 COOH-terminal residues KAKPKFSISPDSL [25]) or Kir6.2 residues 329–344 (DYSKFGNTIKVPTPLC), and each affinity purified by using the corresponding peptide. The SUR1 and Kir6.2 antibodies detected bands of the predicted molecular weights by Western analysis, and their Western and immunohistochemical signals were blocked by the cognate peptides used to generate the antibodies. Guinea pig anti-insulin was obtained from Dako (Carpinteria, CA). AlexaFluor 594 goat anti-rabbit IgG(H+L) and AlexaFluor 488 anti-guinea pig IgG(H+L) were from Molecular Probes. Freshly purified islets, naïve or infected by Ad.Ins-C-GFP for 24–48 h, were fixed with 2% paraformaldehyde in PBS for 20 min, washed in PBS three times, and blocked by incubation in 2% BSA in PBS (pH 7.5) overnight at 4°C. The islets were then incubated with primary antibodies (as indicated, each at 5 μg/ml) in blocking buffer overnight at 4°C. The islets were washed three times with PBS, incubated with labeled secondary antibodies in blocking buffer for 2 h at room temperature, and then washed three times with PBS. Confocal microscopy to detect the immunofluorescence was as described above.

Immunoelectron microscopy.

Islets were prepared for electron microscopy as described (21). Briefly, islets were cryofixed, cut into ultrathin (70–100 nm) sections with a Reichert Ultracut U ultramicrotome/FC4S cryo-attachment, and then lifted on a 2.3 mol/l sucrose droplet on Formvar-coated copper grids. Sections were washed with PBS and PBG buffer (PBS, 0.5% BSA, and 0.15% glycine), blocked with 5% normal goat serum PBG (30 min), labeled with rabbit anti-Kir6.2 “COOH-terminus” at 1:100 in PBG for 1 h, washed in PBG, labeled with goat anti-rabbit gold-conjugated secondary antibodies (each at a dilution of 1:25 for 1 h), washed in PBG and PBS, fixed in 2.5% glutaraldehyde/PBS, washed in PBS, and then washed in double-distilled H2O. Sections were poststained in 2% neutral uranyl acetate (7 min), washed in double-distilled H2O, stained in 4% uranyl acetate (2 min), and then embedded in 1.25% methylcellulose. Labeling was observed on a JEOL JEM 1210 electron microscope (Tokyo) at 80 kV.

Glibenclamide, a potent insulin secretagogue, binds granule-like structures in islet cells.

While covisualizing the arrival of secretagogue with release of insulin granules, we were struck by the observation that the sulfonylurea secretagogue glibenclamide, at low concentrations, localized strongly to the secretory granule itself. We found that either green fluorescent glibenclamide BODIPY FL or red fluorescent glibenclamide BODIPY TR at 40 nmol/l applied to freshly isolated mouse islet cells localized to punctate cytoplasmic structures with spatial and dynamic properties reminiscent of insulin secretory granules (Fig. 1). At up to 10-fold higher concentration, the fluorescent BODIPY dyes by themselves did not localize to subcellular structures, indicating that the glibenclamide moiety directed the fluorescent moieties to the puncta. Furthermore, application of unlabeled 4,000 nmol/l glibenclamide largely prevented labeling of the granules by 40 nmol/l fluorescent glibenclamides. The results suggest high-affinity sulfonylurea receptors localized to the insulin secretory granule, consistent with previous findings (26,27).

Islet glibenclamide-labeled puncta are insulin secretory vesicles.

We demonstrated that the major receptor site for the glibenclamides was localized to insulin secretory granules by covisualizing red glibenclamide together with the green fluorescent “Ins-C-GFP” reporter of insulin granules (21) expressed in the same islets. Application of 40 nmol/l red glibenclamide onto islets expressing Ins-C-GFP resulted in colocalization of the red and green fluorescent reporters at the same cytoplasmic punctate structures (Fig. 2). As before, the red glibenclamide bound to subcellular puncta. Green Ins-C-GFP fluorescence expressed in some of the β-cells of the same islet colocalized with red glibenclamide patterns. We studied this more closely at the single-cell level (Fig. 3). Insulin secretory granules identified by green Ins-C-GFP overlapped extensively with the red fluorescent glibenclamide. Obvious colocalization observed as yellow fluorescence was found by optically sectioning throughout the β-cell. Furthermore, the fluorescent glibenclamide resulted in high-intensity signals at the granule relative to other cell structures, suggesting that a substantial number of high-affinity sulfonylurea receptors are natively expressed at the insulin secretory granule. Little or no labeling of the β-cell membrane, or any other membranes than those of the secretory granules, was detected. The green glibenclamide had been previously shown to bind SUR of bovine monocytes and muscle cells with a subnanomolar apparent dissociation constant (KD) ∼40 nmol/l (22). SUR1 is likely the only receptor of the endocrine pancreas competent to appreciably bind 40-nmol/l fluorescently labeled glibenclamides. The results suggest that the high-affinity sulfonylurea receptor at the insulin granule is SUR1 (previously shown to be a subunit of the pancreatic KATP channel), which also resides on the β-cell plasma membrane (17,12,13).

Expressed SUR1-GFP trafficks to insulin secretory granules.

The results provide strong evidence for high-affinity sulfonylurea receptors localized to insulin secretory granules but do not directly identify the receptor as SUR1. The high intensity of the fluorescent glibenclamide signals at the insulin granule suggests fluorescent tags directly on SUR1 should be detectable. To test this, we determined whether SUR1 tagged with GFP localizes green fluorescence to insulin granules. We used the CMV promoter to express a COOH-terminal GFP fusion to the mouse SUR1 (“SUR1-GFP”) subunit of the mouse pancreatic KATP channel (23). We determined whether islet cells expressing green SUR1-GFP puncta could be colabeled with the red glibenclamide. Figure 4 demonstrates the colabeling at granule-like structures observed. Small and large size classes of punctate structures were labeled by SUR1-GFP and red glibenclamide. The small granules exhibited more uniform diameters averaging ∼400 nm and are bona fide insulin secretory granules, consistent with previous measurements (21). Colocalization of green SUR1-GFP and red fluorescent glibenclamide at secretory granules was evident by the small yellow puncta in merged images. Little or no fluorescence was detectable at the cell perimeter, consistent with a dramatically lower density of KATP channel protein at the plasma membrane (7). The large punctate structures strictly correlated with long-term culturing, which was done to achieve substantial expression of the fluorescent KATP channel subunit-GFP reporters. Large puncta were found in naive islets, as well as islets expressing transgenes, and were detectable by Ins-C-GFP or anti-insulin, indicating a close relationship to insulin granules. The large puncta might plausibly be lysosomal intermediates containing insulin-dense cores (28) or nascent insulin granules that failed to mature (29). Further study of the large puncta was obviated by their absence in fresh islets where the anti-insulin and anti-KATP channel subunit antibodies always identified more characteristic, small-sized insulin secretory granules (see below). Previously, we had demonstrated that the GFP used in the construction of SUR1-GFP, expressed alone, resulted in uniform green fluorescence in the cytoplasm, which accumulates in the nucleus (21). Clearly, SUR1 protein sequences directed the GFP fluorescent moiety not to these compartments but to insulin secretory granules. The SUR1-GFP results, in addition to the fluorescent glibenclamide results, suggest that native SUR1 might be highly trafficked to insulin granules.

Native SUR1 localizes to insulin secretory granules by immunofluorescence.

To directly test for native SUR1 localized to insulin secretory granules, we took an immunohistochemical approach. Antibodies against a COOH-terminal peptide of mouse SUR1 were used with anti-insulin antibodies to probe freshly purified mouse islets. Figure 5 shows extensive colocalization of the anti-SUR1 and anti-insulin antibodies at secretory granules. Colocalization is evident by extensive yellow patterns of fluorescence in the merged image (n = 34 islets in seven experiments). Note that in these islets freshly prepared from the animal, only the small uniformly sized puncta that best approximate insulin granules are observed. Preincubation with the peptide that generated the anti-SUR1 antibodies, or omission of the SUR1 antibodies, resulted in no detectable fluorescence. The results suggest native SUR1 are highly localized to insulin secretory granules, as compared with the β-cell membrane. Because the SUR1 subunit has thus far always associated with the pore-forming subunit Kir6.2 in the KATP channel (6,810), the results might be further supported by testing for a granule site for Kir6.2.

Expressed Kir6.2-GFP trafficks to secretory granules.

We tested for targeting to granules of expressed Kir6.2-GFP fusions of the mouse pancreatic KATP channel (23). Figure 6 shows that simultaneous expression of green fluorescent Kir6.2-GFP and labeling by 40 nmol/l red glibenclamide results in colabeling indicated by yellow puncta in islet cells. Extensive colabeling was observed throughout optical sections in all cells (n = 47 islets in five experiments). The average fluorescence diameter was 0.435 ± 0.231 μm (n = 283 granules in seven cells of five islets in three experiments). A minority of granules showed one but not the other label, consistent with high Kir6.2-GFP expression and low diffusion of red glibenclamide, or low Kir6.2-GFP expression and complete diffusion. No plasma membrane fluorescence was detectable. As mentioned, exogenously expressed GFP alone is not targeted to the insulin granule (21). Localization to secretory granule of pore-forming Kir6.2-GFP fusions, but not GFP alone, suggests that native KATP channel subunits traffick to insulin secretory granules.

Native Kir6.2 localizes to insulin secretory granules.

We tested for native Kir6.2 localized to the granule by labeling with either of two distinct antibodies specific to the COOH-terminal cytoplasmic domain of mouse Kir6.2 and colabeling by anti-insulin. Figure 7 shows that native Kir6.2 is localized to the insulin secretory granule. An antibody to the C-terminus of Kir6.2 directed red fluorescent secondary antibody to insulin granules, identified by the anti-insulin labeled by green fluorescent secondary antibody (n = 24 islets in five experiments). Native Kir6.2 in the β-cell membrane was not detectable under these conditions, in which granule Kir6.2 protein labeling was strong. A second antibody directed against another peptide of the COOH-terminal cytoplasmic domain of Kir6.2 showed highly similar results (data not shown). The Kir6.2 peptides used to generate the antibodies prevented all labeling by their respective antibodies, as did omission of the primary antibodies. Given that Kir6.2 is an integral membrane protein, antibodies against Kir6.2 might label specifically at the membrane perimeter of the secretory granule.

Native Kir6.2 resides in the membrane of the secretory granule.

For the immunoelectron microscopy experiments, we prepared 70- to 100-nm thin sections of mouse islets. Figure 8 shows that gold particle-conjugated secondary antibodies against anti-Kir6.2 COOH-terminus antibodies localized around dense cores, decorating the perimeter of secretory granules, while little or none (≤0.02) localized to plasma membrane, mitochondria, nucleus, or other cellular structures (n = 11 islets in three experiments). The gold particle labeling was associated with the membrane of the secretory granule and not the dense core. The results show that native Kir6.2 subunits are largely localized to the membranes of insulin secretory granules in β-cells.

The main finding of this study is the demonstration by a variety of approaches that the major site for the pancreatic KATP channel is the insulin secretory granule. That the fluorescent glibenclamides labeled native sulfonylurea receptors localized to insulin secretory granules was further supported by the observation that red fluorescent glibenclamide colocalized with the insulin fluorescent reporter, Ins-C-GFP. We have shown that Ins-C-GFP labels secretory granules that can be mobilized and exocytosed by insulin secretagogues (21). Our results corroborate previous evidence for a sulfonylurea receptor at the insulin secretory granule. For example, early work by Hellman et al. (30) showed evidence for dramatic uptake of glibenclamide into islets. Another study combined 3H-glibenclamide labeling, autoradiography, and electron microscopy to determine an insulin granule receptor for the sulfonylurea (26).

We extended our results by using a quite different second approach. Expression in islet β-cells of the pancreatic high-affinity sulfonylurea receptor fused to GFP (SUR1-GFP), but not the GFP expressed alone, localized fluorescence to the same intracellular punctate structures labeled by red fluorescent glibenclamide. Anti-SUR1 antibody immunohistochemistry was a third approach that indicated insulin secretory granules as the major site for SUR1. The three results each support the conclusion that native SUR1 is targeted to insulin secretory granules. Previous observations are consistent with our findings. The pancreatic SUR1 protein has an apparent molecular weight of 140 kDa with more highly glycosylated forms occurring (8). Ozanne et al. (27) showed, by density gradient centrifugation and 3H-glibenclamide labeling, that >90% of the glibenclamide mapped to intracellular structures, with the majority associated with insulin secretory granules. They showed evidence for 3H-glibenclamide binding to intracellular receptors with nanomolar affinity and for 3H-glibenclamide cross-linking to 140- and 170-kDa proteins. Additional results implicate a sulfonylurea receptor protein of 65-kDa in zymogen as well as insulin granules (31), which might have also contributed to the granule fluorescence reported here.

A secretory granule SUR1 suggested its Kir6.2 counterpart in the pancreatic KATP channel would also be targeted to secretory granules. We showed that expressed Kir6.2-GFP fusions localized to insulin granules labeled by red fluorescent glibenclamide. Second, two different anti-Kir6.2 antibodies indicated insulin secretory granules as the major β-cell site for native Kir6.2. Third, immunoelectron microscopy with the anti-Kir6.2 antibodies demonstrated a membrane location of dense-core granules for Kir6.2. Taken together, our results provide the first evidence specifically identifying SUR1 and Kir6.2 localized to insulin secretory granules. Given that SUR1 and Kir6.2 assemble into KATP channels in the endoplasmic reticulum (3234), we propose that pancreatic KATP channels are then targeted by unknown mechanisms to insulin secretory granules. Once inserted into the ER membrane, the KATP channel, like other proteins, is expected to maintain its membrane topology for all cellular membranes. Thus, the SUR1 COOH-terminus and Kir6.2 NH2- and COOH-termini are cytoplasmic at granule as well as plasma membranes.

Implications of granule KATP channels of the endocrine pancreas.

Nearly all studies on glucose-stimulated insulin secretion signaling cite solely a plasma membrane β-cell KATP channel. Early on, Gylfe et al. (35) reviewed numerous published data on islet uptake characteristics of radioactive sulfonylurea compounds. The five sulfonylurea compounds studied, including tolbutamide, showed rapid saturated binding with little uptake, suggesting interactions with the surface of the β-cells. Glibenclamide, however, did not rapidly reach uptake equilibrium, but rather progressively accumulated in substantial quantity within the islets (30). While discussing this exceptional mode of interaction of glibenclamide, Gylfe et al. nevertheless concluded that the insulin-releasing action of these drugs is due to binding with the β-cell membrane, because most of the sulfonylurea compounds were not appreciably internalized yet act as insulin secretagogues. The overall model presented, that cell-surface interaction of sulfonylureas decreases potassium permeability, leading to Ca2+ influx and insulin release, seemed reasonable at the time and explains much of what we currently know of first-phase insulin release. Like most studies on the action of sulfonylureas on insulin secretion, these studies fail to address any other cellular domain but the plasma membrane. Yet the experimental results are nearly always interpreted to mean that the isulinotropic action of sulfonylurea compounds is exclusively at the plasma membrane, and not internalized. Our results indicate that this view is incomplete and cellular mechanisms of pancreatic KATP channels might be productively studied at the insulin secretory granule membrane, as well as the plasma membrane.

Whenever we observed intense fluorescence localized to secretory granules, little if any cell membrane labeling was detected. The relative density of the pancreatic KATP channel in the secretory granule membrane is likely high relative to the β-cell membrane. The observation is consistent with electrophysiological estimates of the plasma membrane KATP channel, where hundreds are thought to reside (7). On one hand, the KATP channels spread across the β-cell plasma membrane would be largely undetectable by the confocal microscopy conditions used here, but are readily detectable by electrophysiology. On the other hand, the electrophysiology that detects KATP channels at the cell membrane is incapable of testing for KATP channels at granule membranes. Interestingly, glibenclamide is distinguished from other sulfonylureas, not only by its exceptional ability to be internalized within β-cells (30,35), but also by its superior secretory efficacy (3). The observations call for sulfonylurea drug design in the future to specifically target the intracellular secretory granule sites.

Our results suggest there are two roles for pancreatic KATP channels that depend on cellular position. KATP channels localized to the β-cell membrane play a well-established role in coupling glucose metabolism to plasma membrane excitability that switches calcium influx on for release. The calcium influx triggers exocytosis of primed insulin granules docked at the β plasma membrane, observed as first-phase release (36). KATP channels localized to the insulin granule membrane might also play a role in coupling glucose metabolism in a dose-dependent manner to granule transport and exocytosis, observed as second-phase release (see below). Transgenic studies show that inactivation of the pore-forming Kir6.2 subunit renders glucose ineffective on insulin secretion from isolated islets, with a very small first-phase possibly remaining (37). Transgenic inactivation of SUR1 also disrupts the response of both phases to glucose, where only a dramatically delayed and blunted release was found that might or might not be mechanistically related to wild-type second-phase release (38). Even with calcium chronically elevated by the SUR1 inactivation, second- as well as first-phase response to elevated glucose was disrupted, consistent with granule KATP (gKATP) channels mediating an amplifying action of glucose on insulin release.

gKATP channels are designed and positioned to confer glucose dose dependency to the second phase of insulin release, where calcium is unlikely rate limiting (14,16,39,40). There is evidence that the ATP/ADP ratio exerts control strength over signal flow, coupling glucose metabolism and insulin exocytosis rates. In particular, increases in ATP/ADP ratios that signal elevated blood glucose levels accelerate steps distal to calcium influx through the plasma membrane, including insulin granule translocation and exocytosis (16,18,19,41). With ATP sites on Kir6.2 that inhibit activity and ADP sites on SUR1 that antagonize the inhibition, gKATP channels are designed as ATP and ADP sensors of glucose metabolism. The increased ATP/ADP ratio could inhibit granule membrane potassium conductance of the gKATP channel, leading to changes in granule membrane potential, ion composition, or both. Verdugo and colleagues (42,43) have reported evidence that secretory granules require potassium channels for appropriate release. The gKATP channel might not only function as a channel as it does in the plasma membrane. The gKATP channel might play additional roles due to different ligand, phospholipid, and protein interactions between the two membrane domains. Thus, via increases in ATP and decreases in ADP that combine with changes in intracellular calcium and phosphoinositides, glucose metabolism could alter gKATP channel activities, involving interactions with lipids, motors, and associated proteins that mediate transport, recruitment, and exocytosis of the granule at the β-cell membrane (4450). Whereas the minority of KATP channels in the plasma membrane provide on/off switch regulation for Ca2+ influx that mediates first-phase release and is permissive for second-phase release (11,1418), the majority of KATP channels in secretory granule membranes are situated to accelerate, in a graded way with glucose metabolism, granule translocation, priming, and exocytosis rates that otherwise limit second-phase insulin release.

FIG. 1.

Fluorescent sulfonylureas bind punctate structures within cells of the endocrine pancreas. A: Green glibenclamide BODIPY FL labels subcellular cytoplasmic structures that resemble secretory granules within a single islet cell. Z sections (left to right and down) of a single isolated cell were taken every 0.5 μm. B: Red glibenclamide BODIPY TR labels similar granule-like structures within a pair of islet cells. Every 0.5 μm (left to right and down), z sections are shown of a pair of isolated cells. The plasma membrane show no detectable fluorescence after labeling by either the green or red fluorescent sulfonylurea. Each was used at 40 nmol/l on freshly isolated live cells gently dissociated from mouse islets in RPMI-1640 culture medium with 7.5 mmol/l glucose. PlanApo, 60X oil, NA 1.4. Bar equals 2 μm.

FIG. 1.

Fluorescent sulfonylureas bind punctate structures within cells of the endocrine pancreas. A: Green glibenclamide BODIPY FL labels subcellular cytoplasmic structures that resemble secretory granules within a single islet cell. Z sections (left to right and down) of a single isolated cell were taken every 0.5 μm. B: Red glibenclamide BODIPY TR labels similar granule-like structures within a pair of islet cells. Every 0.5 μm (left to right and down), z sections are shown of a pair of isolated cells. The plasma membrane show no detectable fluorescence after labeling by either the green or red fluorescent sulfonylurea. Each was used at 40 nmol/l on freshly isolated live cells gently dissociated from mouse islets in RPMI-1640 culture medium with 7.5 mmol/l glucose. PlanApo, 60X oil, NA 1.4. Bar equals 2 μm.

Close modal
FIG. 2.

The insulin granule reporter green Ins-C-GFP colocalizes with red fluorescent glibenclamide receptor sites within cells of the endocrine pancreas. A: Cells within an islet infected with Ad.Ins-C-GFP after 2 days of expression. A subset of cells within the islet shows green fluorescent insulin granules containing green fluorescent Ins-C-GFP. The subset is due in part to adenovirus typically infecting a minority of islets cells and in part to the Ins-C-GFP transcribed by the insulin II gene promoter expressing only in insulin-secreting β-cells, which are ∼60% of the total islet cells. B: Glibenclamide BODIPY TR (red fluorescence). C: Merge of A and B. Note perimeter labeling reflects labeled granules lined up along cell membrane. Plasma membrane labeling would be at the diffraction limit, resulting in far thinner, perfectly uniform fluorescent lines that would not exhibit variable thickness. PlanApo, 60X oil, NA 1.4. Bar equals 2 μm.

FIG. 2.

The insulin granule reporter green Ins-C-GFP colocalizes with red fluorescent glibenclamide receptor sites within cells of the endocrine pancreas. A: Cells within an islet infected with Ad.Ins-C-GFP after 2 days of expression. A subset of cells within the islet shows green fluorescent insulin granules containing green fluorescent Ins-C-GFP. The subset is due in part to adenovirus typically infecting a minority of islets cells and in part to the Ins-C-GFP transcribed by the insulin II gene promoter expressing only in insulin-secreting β-cells, which are ∼60% of the total islet cells. B: Glibenclamide BODIPY TR (red fluorescence). C: Merge of A and B. Note perimeter labeling reflects labeled granules lined up along cell membrane. Plasma membrane labeling would be at the diffraction limit, resulting in far thinner, perfectly uniform fluorescent lines that would not exhibit variable thickness. PlanApo, 60X oil, NA 1.4. Bar equals 2 μm.

Close modal
FIG. 3.

Single-cell detail of Ins-C-GFP colocalized with red fluorescent glibenclamide. A: Green Ins-C-GFP identifies insulin secretory granules of a cell within an islet. B: Glibenclamide BODIPY TR (red fluorescence) localization to puncta. Most of the red glibenclamide overlaps at punctate structures with the green Ins-C-GFP, but there are green granules that are not also red and there are red structures without green Ins-C-GFP. C. Merge of the red and green images; yellow intensity indicates punctate structures colocalizing red glibenclamide and the green insulin secretory granule reporter Ins-C-GFP. D: Optical sections, 2 μm apart, including the section exploded in the previous panels. PlanApo, 60X oil, NA 1.4.

FIG. 3.

Single-cell detail of Ins-C-GFP colocalized with red fluorescent glibenclamide. A: Green Ins-C-GFP identifies insulin secretory granules of a cell within an islet. B: Glibenclamide BODIPY TR (red fluorescence) localization to puncta. Most of the red glibenclamide overlaps at punctate structures with the green Ins-C-GFP, but there are green granules that are not also red and there are red structures without green Ins-C-GFP. C. Merge of the red and green images; yellow intensity indicates punctate structures colocalizing red glibenclamide and the green insulin secretory granule reporter Ins-C-GFP. D: Optical sections, 2 μm apart, including the section exploded in the previous panels. PlanApo, 60X oil, NA 1.4.

Close modal
FIG. 4.

Exogenously expressed SUR1-GFP colocalizes with red fluorescent glibenclamide at insulin secretory granules. A: Localization of SUR1-GFP (green fluorescence) to punctate structures of a cell within an islet. B: Localization of acutely applied glibenclamide BODIPY TR (red fluorescence). C: Merge of green SUR1-GFP and red glibenclamide. Yellow intensity indicates punctate structures colocalizing the green SUR1-GFP and the red glibenclamide. Images were collected sequentially with 488-nm line excitation followed by 543-nm line excitation and then merged offline. D: Optical sections, 2 μm apart. Note that large puncta were detected by SUR1-GFP only after long-term culturing needed to obtain substantial fluorescent signal. The large puncta were also labeled consequent to long-term culturing of naïve as well as transgenic islets by anti-insulin antibodies, indicating a close relationship with insulin granules. The small puncta best approximate insulin granule size. PlanApo 60X oil, NA 1.4.

FIG. 4.

Exogenously expressed SUR1-GFP colocalizes with red fluorescent glibenclamide at insulin secretory granules. A: Localization of SUR1-GFP (green fluorescence) to punctate structures of a cell within an islet. B: Localization of acutely applied glibenclamide BODIPY TR (red fluorescence). C: Merge of green SUR1-GFP and red glibenclamide. Yellow intensity indicates punctate structures colocalizing the green SUR1-GFP and the red glibenclamide. Images were collected sequentially with 488-nm line excitation followed by 543-nm line excitation and then merged offline. D: Optical sections, 2 μm apart. Note that large puncta were detected by SUR1-GFP only after long-term culturing needed to obtain substantial fluorescent signal. The large puncta were also labeled consequent to long-term culturing of naïve as well as transgenic islets by anti-insulin antibodies, indicating a close relationship with insulin granules. The small puncta best approximate insulin granule size. PlanApo 60X oil, NA 1.4.

Close modal
FIG. 5.

Anti-SUR1 peptide antibodies localize at secretory granules identified by anti-insulin. A: Anti-insulin antibodies (green fluorescence) identifiy secretory granules in a β-cell gently dissociated from freshly purified islets. B: Anti-SUR1 peptide antibodies identify similar pattern of punctate structures in the same cell. C: Merge of green insulin secretory granule labeling and red SUR1 labeling. PlanApo, 60X oil, NA 1.4.

FIG. 5.

Anti-SUR1 peptide antibodies localize at secretory granules identified by anti-insulin. A: Anti-insulin antibodies (green fluorescence) identifiy secretory granules in a β-cell gently dissociated from freshly purified islets. B: Anti-SUR1 peptide antibodies identify similar pattern of punctate structures in the same cell. C: Merge of green insulin secretory granule labeling and red SUR1 labeling. PlanApo, 60X oil, NA 1.4.

Close modal
FIG. 6.

Exogenously expressed Kir6.2-GFP trafficking to secretory granules colabeled by red glibenclamide BODIPY TR. A: Localization of Kir6.2-GFP (green fluorescence) labels punctate structures in a cell within an islet. B: Localization of acutely applied glibenclamide BODIPY TR (red fluorescence) to punctate structures within the same cell. C: Merge of previous images where yellow reflects colocalization. D: Optical sections, 2 μm apart, including the section exploded in the previous panels. The large puncta are associated with long-term culture, which was routinely done to obtain significant punctate fluorescence from Kir6.2-GFP. PlanApo, 60X oil, NA 1.4.

FIG. 6.

Exogenously expressed Kir6.2-GFP trafficking to secretory granules colabeled by red glibenclamide BODIPY TR. A: Localization of Kir6.2-GFP (green fluorescence) labels punctate structures in a cell within an islet. B: Localization of acutely applied glibenclamide BODIPY TR (red fluorescence) to punctate structures within the same cell. C: Merge of previous images where yellow reflects colocalization. D: Optical sections, 2 μm apart, including the section exploded in the previous panels. The large puncta are associated with long-term culture, which was routinely done to obtain significant punctate fluorescence from Kir6.2-GFP. PlanApo, 60X oil, NA 1.4.

Close modal
FIG. 7.

Anti-Kir6.2 peptide antibodies localize at secretory granules identified by anti-insulin. A: Anti-insulin antibodies (green fluorescence) labeling in a cluster of β-cells within a freshly purified islet. B: Anti-Kir6.2 peptide antibodies (red fluorescence) applied to the same cells. C: Merge of the green insulin and red Kir6.2 images where yellow shows areas of obvious colocalization of insulin granules and Kir6.2. D: Localization of insulin secretory granules by anti-insulin (green fluorescence) in a β-cell dissociated from a freshly purified islet. E: Localization of anti-Kir6.2 antibodies (red fluorescence) in same β-cell. F. Merge of previous images where yellow shows obvious colocalization of green insulin and red Kir6.2 labeling. PlanApo, 60X oil, NA 1.4.

FIG. 7.

Anti-Kir6.2 peptide antibodies localize at secretory granules identified by anti-insulin. A: Anti-insulin antibodies (green fluorescence) labeling in a cluster of β-cells within a freshly purified islet. B: Anti-Kir6.2 peptide antibodies (red fluorescence) applied to the same cells. C: Merge of the green insulin and red Kir6.2 images where yellow shows areas of obvious colocalization of insulin granules and Kir6.2. D: Localization of insulin secretory granules by anti-insulin (green fluorescence) in a β-cell dissociated from a freshly purified islet. E: Localization of anti-Kir6.2 antibodies (red fluorescence) in same β-cell. F. Merge of previous images where yellow shows obvious colocalization of green insulin and red Kir6.2 labeling. PlanApo, 60X oil, NA 1.4.

Close modal
FIG. 8.

Anti-Kir6.2 antibodies localize to secretory granule perimeters. A: Immunoelectron microscopy of dense core secretory granules with anti-Kir6.2 peptide antibodies labeled with gold particle-conjugated secondary antibody. Mitochondrion in upper left and other structures did not localize gold particles. B: Independent experiment also showing anti-Kir6.2 labeling of dense-core secretory granules. Note frequent separation of gold particle labels from dense core, consistent with secretory granule membrane localization of Kir6.2. Cells imaged were from thin sections of intact islets. Scale bar is 200 nm. Magnification is ×30,000.

FIG. 8.

Anti-Kir6.2 antibodies localize to secretory granule perimeters. A: Immunoelectron microscopy of dense core secretory granules with anti-Kir6.2 peptide antibodies labeled with gold particle-conjugated secondary antibody. Mitochondrion in upper left and other structures did not localize gold particles. B: Independent experiment also showing anti-Kir6.2 labeling of dense-core secretory granules. Note frequent separation of gold particle labels from dense core, consistent with secretory granule membrane localization of Kir6.2. Cells imaged were from thin sections of intact islets. Scale bar is 200 nm. Magnification is ×30,000.

Close modal

This study was supported by the Department of Cell Biology and Physiology of University of Pittsburgh School of Medicine, the Juvenile Diabetes Research Foundation (grant no. 4-1999-845), and the National Science Foundation (grant no. MCB 9817116).

The authors thank Drs. Meir Aridor, Bob Bridges, Ray Frizzell, Linton Traub, and Massimo Trucco for helpful discussions, and Rita Bottino, Bala Balamurugan, and Yigang Chen for generously providing highly pure mouse islets. This study is dedicated to the memory of Paul F. Drain, who taught us measure and patience.

1.
Schwanstecher M, Schwanstecher C, Dickel C, Chudziak F, Moshiri A, Panten U: Location of the sulphonylurea receptor at the cytoplasmic face of the β-cell membrane.
Br J Pharmacol
113
:
903
–911,
1994
2.
Aguilar-Bryan L, Nichols CG, Weschler SW, Clement IV JP, Boyd III AE, Gonzalez G, Herrera-Sosa H, Nguy K, Bryan J, Nelson DA: Cloning of the β cell high-affinity sulfonylurea receptor: a regulator of insulin secretion.
Science
268
:
423
–426,
1995
3.
Ashcroft FM: Adenosine 5′-triphosphate-sensitive potassium channels.
Annu Rev Neurosci
11
:
97
–118,
1988
4.
Babenko AP, Aguilar-Bryan L, Bryan J: A view of SUR/Kir6.X, KATP channels.
Annu Rev Physiol
60
:
667
–687,
1998
5.
Seino S: ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies.
Annu Rev Physiol
61
:
337
–362,
1999
6.
Inagaki N, Gonoi T, Clement JPT, Namba N, Inazawa J, Gonzalez G, Aguilar-Bryan L, Seino S, Bryan J: Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor.
Science
270
:
1166
–1170,
1995
7.
Cook DL, Satin LS, Ashford ML, Hales CN: ATP-sensitive K+ channels in pancreatic β-cells: spare-channel hypothesis.
Diabetes
37
:
495
–498,
1988
8.
Clement IV JP, Kunjilwar K, Gonzalez G, Schwanstecher M, Panten U, Aguilar-Bryan L, Bryan J: Association and stoichiometry of KATP channel subunits.
Neuron
18
:
827
–838,
1997
9.
Inagaki N, Gonoi T, Seino S: Subunit stoichiometry of the pancreatic beta-cell ATP-sensitive K+ channel.
FEBS Lett
409
:
232
–236,
1997
10.
Shyng SL, Nichols CG: Octameric stoichiometry of the KATP channel complex.
J Gen Physiol
110
:
655
–664,
1997
11.
Henquin JC: Triggering and amplifying pathways of regulation of insulin secretion by glucose.
Diabetes
49
:
1751
–1760,
2000
12.
Cook DL, Hales CN: Intracellular ATP directly blocks K+ channels in pancreatic β-cells.
Nature
311
:
271
–273,
1984
13.
Ashcroft FM, Harrison DE, Ashcroft SJ: Glucose induces closure of single potassium channels in isolated rat pancreatic β-cells.
Nature
312
:
446
–448,
1984
14.
Gembal M, Gilon P, Henquin JC: Evidence that glucose can control insulin release independently from its action on ATP-sensitive K+ channels in mouse β cells.
J Clin Invest
89
:
1288
–1295,
1992
15.
Sato Y, Aizawa T, Komatsu M, Okada N, Yamada T: Dual functional role of membrane depolarization/Ca2+ influx in rat pancreatic β-cell.
Diabetes
41
:
438
–443,
1992
16.
Gembal M, Detimary P. Gilon P, Gao ZY, Henquin JC: Mechanism by which glucose can control insulin release independently from its action on adenosine triphosphate-sensitive K+ channels in mouse β cells.
J Clin Invest
91
:
871
–880,
1993
17.
Aizawa T, Sato Y, Ishihara F, Taguchi N, Komatsu M, Suzuki N, Hashizume K, Yamada T: ATP-sensitive K+ channel-independent glucose action in rat pancreatic β cell.
Am J Physiol
266
:
C622
–C627,
1994
18.
Sato Y, Henquin JC: The KATP channel-independent pathway of regulation of insulin secretion by glucose: in search of the underlying mechanism.
Diabetes
47
:
1713
–1721,
1998
19.
Detimary P, Van den Berghe G, Henquin JC: Concentration dependence and time course of the effects of glucose: on adenine and guanine nucleotides in mouse pancreatic islets.
J Biol Chem
271
:
20559
–20565,
1996
20.
Liu M, Shapiro ME: A new method for isolation of murine islets with markedly improved yields.
Transplant Proc
27
:
3208
–3210,
1995
21.
Watkins S, Geng X, Li L, Papworth G, Robbins PD, Drain P: Imaging secretory vesicles by fluorescent protein insertion into propetide rather than mature secreted peptide.
Traffic
3
:
461
–471,
2002
22.
Löhrke B, Derno M, Krüger B, Viergutz T, Matthes HD, Jentsch W: Expression of sulphonylurea receptors in bovine monocytes from animals with a different metabolic rate.
Pflügers Arch-Eur J physiol
434
:
712
–720,
1997
23.
Drain P, Li L, Wang J: KATP channel inhibition by ATP requires distinct functional domains of the cytoplasmic C terminus of the pore-forming subunit.
Proc Natl Acad Sci U S A
95
:
13953
–13958,
1998
24.
Suzuki M, Fujikura K, Kotake K, Inagaki N, Seino S, Takata K: Immuno-localization of sulphonylurea receptor 1 in rat pancreas.
Diabetologia
42
:
1204
–1211,
1999
25.
Suzuki M, Fujikura K, Inagaki N, Seino S, Takata K: Localization of the ATP-sensitive K+ channel subunit Kir6.2 in mouse pancreas.
Diabetes
46
:
1440
–1444,
1997
26.
Carpentier JL, Sawano F, Ravazzola M, Malaisse WJ: Internalization of 3H-glibenclamide in pancreatic islet cells.
Diabetologia
29
:
259
–261,
1986
27.
Ozanne SE, Guest PC, Hutton JC, Hales CN: Intracellular localization and molecular heterogeneity of the sulphonylurea receptor in insulin-secreting cells.
Diabetologia
38
:
277
–282,
1995
28.
Schnell Landström AH, Westman J, Håkan Borg LA: Lysosomes and pancreatic islet function: time course of insulin biosynthesis, insulin secretion, and lysosomal transformation after rapid changes in glucose concentration.
Diabetes
37
:
309
–316,
1988
29.
Molinete M, Dupuisw S, Brodsky FM, Halban PA: Role of clathrin in the regulated secretory pathway of pancreatic β-cells.
J Cell Sci
114
:
3059
–3066,
2001
30.
Hellman B, Sehlin J, Taljedal IB: Glibenclamide is exceptional among hypoglycaemic sulphonylureas in accumulating progressively in beta-cell-rich pancreatic islets.
Acta Endocrinol
105
:
385
–390,
1984
31.
Thévenod F, Anderie I, Schulz I: Monoclonal antibodies against MDR1 P-glycoprotein inhibit chloride conductance and label a 65-kDa protein in pancreatic zymogen granule membranes.
J Biol Chem
262
:
24410
–24417,
1994
32.
Sharma N, Crane A, Clement IV JP, Gonzalaz G, Babenko AP, Bryan J, Aguilar-Bryan L: The C terminus of SUR1 is required for trafficking of KATP channels.
J Biol Chem
274
:
20628
–20632,
1999
33.
Zerangue N, Schwappach B, Jan YU, Jan LY: A new ER trafficking signal regulates the subunit stoichiometry of plasma membrane KATP channels.
Neuron
22
:
537
–548,
1999
34.
Schwappach B, Zerangue N, Jan YN, Jan LY: Molecular basis for KATP assembly: transmembrane interactions mediate association of a K+ channel with an ABC transporter.
Neuron
26
:
155
–167,
2000
35.
Gylfe E, Hellman B, Sehlin J, Taljedal B: Interaction of sulfonylurea with the pancreatic β-cell.
Experientia
40
:
1126
–1134,
1984
36.
Daniel S, Noda M, Straub SG, Sharp GW: Identification of the docked granule pool responsible for the first phase of glucose-stimulated insulin secretion.
Diabetes
48
:
1686
–1690,
1999
37.
Miki T, Nagashima K, Tashiro F, Kotake K, Yoshitomi H, Tamamoto A, Gonoi T, Iwanaga T, Miyazaki J-I, Seino S: Defective insulin secretion and enhanced insulin action in KATP channel-deficient mice.
Proc Natl Acad Sci U S A
95
:
10402
–10406,
1998
38.
Seghers V, Nakazaki M, DeMayo F, Aguilar-Bryan L, Bryan J: SUR1 knockout mice: a model for KATP channel-independent regulation of insulin secretion.
J Biol Chem
275
:
9270
–9277,
2000
39.
Komatsu M, Schermerhorn T, Noda M, Straub SG, Aizawa T, Sharp GWG: Augmentation of insulin release by glucose in the absence of extracellular Ca2+: new insights into stimulus-secretion coupling.
Diabetes
46
:
1928
–1938,
1997
40.
Henquin JC, Ishiyama N, Nenquin M, Ravier MA, Jonas JC: Signals and pools underlying biphasic insulin secretion.
Diabetes
51 (Suppl. 1)
:
S60
–S67,
2002
41.
Eliasson L, Renström E, Ding WG, Proks P, Rorsman P: Rapid ATP-dependent priming of secretory granules precedes Ca2+ induced exocytosis in mouse pancreatic β cells.
J Physiol
503
:
399
–412,
1997
42.
Nguyen T, Chin WC, Verdugo P: Role of Ca2+/K+ ion exchange in intracellular storage and release of Ca2+.
Nature
395
:
908
–912,
1998
43.
Quesada I, Chin WC, Steed J, Campos-Bedolla P, Verdugo P: Mouse mast cell secretory granules can function as intracellular ionic oscillators.
Biophys J
80
:
2133
–2139,
2001
44.
Donelan MJ, Morfini G, Julyan R, Sommers S, Hays L, Kajio H, Briaud I, Easom RA, Molkentin JD, Brady ST, Rhodes CJ: Ca2+-dependent dephosphorylation of kinesin heavy chain on beta-granules in pancreatic beta-cells. Implications for regulated beta-granule transport and insulin exocytosis.
J Biol Chem
277
:
24232
–42,
2002
45.
Koriyama N, Kakei M, Nakazaki M, Yaekura K, Ichinari K, Gong Q, Morimitsu S, Yada T, Tei C: PIP2 and ATP cooperatively prevent cytosolic Ca2+-induced modification of ATP-sensitive K+ channels in rat pancreatic β-cells.
Diabetes
49
:
1830
–1839,
2000
46.
Baukrowitz T, Schulte U, Oliver D, Herlitze S, Tucker SJ, Ruppersbrerg JP, Fakler B: PIP2 and PIP as determinants for ATP inhibition of KATP channels.
Science
282
:
1141
–1144,
1998
47.
Baukrowitz T, Fakler B: KATP channels gated by intracellular nucleotides and phospholipids.
Eur J Biochem
267
:
5842
–5848,
2000
48.
Hilgemann DW, Ball R: Regulation of cardiac Na+, Ca2+ exchange and KATP potassium channels by PIP2.
Science
273
:
956
–959,
1996
49.
Shyng SL, Nichols CG: Membrance phospholipid control of nucleotide sensitivity of KATP channel.
Science
282
:
1138
–1141,
1998
50.
Simonsen A, Wurmser AE, Emr SD, Stenmark H: The role of phosphoinositides in membrane transport.
Curr Opin Cell Biol
13
:
485
–492,
2001

Address correspondence and reprint requests to Peter Drain, Biomedical Science Tower South, Room 323, 3500 Terrace St., Pittsburgh, PA 15261. E-mail: [email protected].

Received for publication 30 August 2002 and accepted in revised form 10 December 2002.

gKATP, granule ATP-sensitive potassium channel; KATP channel, ATP-sensitive potassium channel; KD, apparent dissociation constant.